Monte Rosa Therapeutics, Inc.

https://www.monterosatx.com/
Tags:BiopharmaBioTechChemicalDesignDrugPlatform
Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-causing proteins. The company has developed a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles.
Location: United States, Boston
Total raised: $191M

Investors 2

DateNameWebsite
31.10.2020Aisling Ca...aislingcap...
02.10.2020GVgv.com

Funding Rounds 2

DateSeriesAmountInvestorsDeal News
15.03.2021Series C$95M-Monte Rosa...
24.09.2020Series B$96M-Monte Rosa...

Mentions in press and media 7

DateTitleDescriptionCategoryAuthorSource
19.03.2021Monte Rosa...Monte Rosa was launched from f...Investment-startuptic...
16.03.2021Monte Rosa...Monte Rosa Therapeutics, a Bos...USA-finsmes.co...
15.03.2021Monte Rosa...Monte Rosa Therapeutics has ra...--pitchbook....
11.03.2021New appoin...Versantis AG, a clinical-stage...People-startuptic...
28.10.2020Seasoned e...As of 9 November 2020, Annett ...People-startuptic...
25.09.2020Monte Rosa...Through this approach Monte Ro...Investment...-startuptic...
24.09.2020Monte Rosa...“We are pleased to have the ...--medcitynew...